NEW YORK, July 15, 2015 /PRNewswire/ — Dilated cardiomyopathy is an important cause of heart failure and is one of the leading indications for heart transplantation across the globe. It is characterized by the enlargement of ventricular chamber along with systolic dysfunction. Dilated cardiomyopathy can develop at any age but it is more common among people aged between 20 years and 60 years. According to American Society for Clinical Investigation about 25% – 50% of the total dilated cardiomyopathy cases are genetically caused, owing to mutation in genes encoding for cytoskeleton, contractile, or other proteins in myocardial cells.
The global dilated cardiomyopathy therapeutics market is studied in this report from three perspectives: by drug class, by pipelined products and by geography. Dilated cardiomyopathy therapeutics market by drug class encompasses aldosterone antagonists, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and beta-blockers. A detailed market analysis and forecast for each of these segments have been provided in this study, in terms of market revenue (USD million) for the period 2012 to 2020. The report also provides the compounded annual growth rate (CAGR %) for each of these segments for the forecast period from 2014 to 2020, considering 2012 and 2013 as base years. Geographic regions analyzed for this market include North America, Europe, Asia Pacific and Rest of the World. The North American market comprises the United States and Canada. The European market includes countries such as the U.K., Germany, Italy, and Spain that majorly contribute towards the growth of this region. Similarly, the Asia Pacific market primarily considers India, China, Japan, Singapore, and Australia, along with other smaller markets.
The market overview section of the report demonstrates the major factors determining the market dynamics such as drivers, restraints and opportunities that influence the current as well as future status of this industry. The market overview section of the report also includes qualitative and quantitative analysis of the competitive landscape covering market share analysis by key players.
The study also suggests a list of recommendations which would be useful for existing and future market players in decision making for business growth. Pipeline analysis (Phase I and Phase II) for dilated cardiomyopathy therapeutics market has also been covered in the report. The report concludes with the company profiles section, which illustrates key information about the major players in this market such as company overview, financial overview, product portfolio, business strategies and recent developments. Key players profiled in the report include Array BioPharma, Inc., AstraZeneca plc, Celladon Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd, and Vericel Corporation.
The global dilated cardiomyopathy therapeutics market is segmented into the following categories:
Dilated cardiomyopathy therapeutics market, by drug class
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers (ARBs)
Dilated cardiomyopathy therapeutics market, by pipeline drugs
Dilated cardiomyopathy therapeutics market, by geography
Rest of the World (RoW)
Read the full report: http://www.reportlinker.com/p02878121-summary/view-report.html
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need – instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001